Kalita Deepjyoti, Bhatia Mohit, Rekha Udayakumar Sasi, Singh Arpana
Department of Microbiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
J Pharm Bioallied Sci. 2022 Jan-Mar;14(1):46-51. doi: 10.4103/jpbs.jpbs_658_21. Epub 2022 May 19.
There was a global surge in cases of mucormycosis in COVID-19 patients during the second wave of the pandemic in 2021, reported especially from India. Various predisposing factors such as diabetes mellitus, rampant use of corticosteroids, and COVID-19 per se may be responsible for this spike. Some public health experts have postulated that the epidemiological link between the Delta variant of SARS-CoV-2 and mucormycosis should be explored.
A retrospective exploratory study was conducted, in which data of 15 laboratory-confirmed cases of COVID-19 with mucormycosis and/or aspergillosis co-infections were collected after obtaining approval from the institute's ethics committee. These patients were admitted to the Mucor wards of our hospital. The positive COVID-19 status of these patients was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). The residual SARS-CoV-2 RNA containing elutes of these patients were stored at -80°C in deep freezers and subjected to whole-genome sequencing in June 2021 at the National Centre for Disease Control (NCDC), New Delhi, India as part of the Indian SARS-CoV-2 Genomic Consortia (INSACOG) program. Concomitant fungal infections in these patients were diagnosed by KOH wet mount and fungal culture as per standard guidelines. Descriptive statistics in the form of percentages and median were used to report the findings.
Periorbital swelling and ocular pain (14/15; 93.33%), followed by facial swelling (11/15; 73.33%) and nasal obstruction (9/15; 60%), were the most common clinical features observed in these patients. was the most common causative fungal agent (12/15; 80%). The majority of the patients (9/13; 69.23%) were infected with the Delta variant of SARS-CoV-2.
COVID-associated mucormycosis seems to be multifactorial in origin. Although there may be a possible association between mucormycosis and the Delta variant, more studies should be conducted to explore this seemingly reasonable proposition.
在2021年第二波新冠疫情大流行期间,全球范围内新冠患者的毛霉病病例激增,尤其是在印度有相关报道。糖尿病、大量使用皮质类固醇等各种诱发因素以及新冠病毒本身可能是导致这一激增的原因。一些公共卫生专家推测,应探索严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的德尔塔变异株与毛霉病之间的流行病学联系。
进行了一项回顾性探索性研究,在获得该机构伦理委员会批准后,收集了15例实验室确诊的新冠合并毛霉病和/或曲霉病感染病例的数据。这些患者被收治到我院的毛霉病房。通过逆转录聚合酶链反应(RT-PCR)确认了这些患者的新冠病毒阳性状态。这些患者含有残留SARS-CoV-2 RNA的洗脱液于-80°C保存在低温冰箱中,并于2021年6月在印度新德里的国家疾病控制中心(NCDC)作为印度SARS-CoV-2基因组联盟(INSACOG)项目的一部分进行全基因组测序。按照标准指南,通过氢氧化钾湿片和真菌培养对这些患者的合并真菌感染进行诊断。以百分比和中位数形式的描述性统计用于报告研究结果。
眶周肿胀和眼痛(14/15;93.33%),其次是面部肿胀(11/15;73.33%)和鼻塞(9/15;60%),是这些患者中观察到的最常见临床特征。 是最常见的致病真菌(12/15;80%)。大多数患者(9/13;69.23%)感染了SARS-CoV-2的德尔塔变异株。
新冠相关毛霉病似乎起源于多因素。虽然毛霉病与德尔塔变异株之间可能存在关联,但应开展更多研究来探索这一看似合理的推测。